Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DERM
stocks logo

DERM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
19.34M
+41.98%
-0.045
-156.25%
20.42M
+55.42%
-0.030
-83.33%
24.88M
+65.77%
0.050
-131.25%
Estimates Revision
The market is revising Downward the revenue expectations for Journey Medical Corporation (DERM) for FY2025, with the revenue forecasts being adjusted by -6.26% over the past three months. During the same period, the stock price has changed by 11.41%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+47.94%
In Past 3 Month
Stock Price
Go Up
up Image
+11.41%
In Past 3 Month
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.810
sliders
Low
13.00
Averages
13.00
High
13.00
Current: 7.810
sliders
Low
13.00
Averages
13.00
High
13.00
Alliance Global
Buy
maintain
$10 -> $16
2025-11-13
Reason
Alliance Global
Price Target
$10 -> $16
2025-11-13
maintain
Buy
Reason
Alliance Global raised the firm's price target on Journey Medical to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites enthusiasm in the Emrosi launch for the target boost. It increased its peak revenue forecast to $250M from $200M for the drug.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$13
2025-08-25
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$13
2025-08-25
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical with a Buy rating and $13 price target. The firm believes the company's Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.
Lake Street
Buy
maintain
$9 -> $13
2025-08-13
Reason
Lake Street
Price Target
$9 -> $13
2025-08-13
maintain
Buy
Reason
Lake Street raised the firm's price target on Journey Medical to $13 from $9 and keeps a Buy rating on the shares after the company reported Q2 revenue higher than the firm's estimate and consensus. Though it is still early, signals from the ongoing launch of Emrosi "appear quite positive," the analyst tells investors in a post-earnings note.
B. Riley
Mayank Mamtani
Buy
maintain
$9 -> $12
2025-07-30
Reason
B. Riley
Mayank Mamtani
Price Target
$9 -> $12
2025-07-30
maintain
Buy
Reason
B. Riley analyst Mayank Mamtani raised the firm's price target on Journey Medical to $12 from $9 and keeps a Buy rating on the shares following a transfer of coverage. The firm expects increased visibility into Emrosi's early launch performance with the Q2 results in mid-August.
Alliance Global Partners
Buy
downgrade
$10
2025-05-15
Reason
Alliance Global Partners
Price Target
$10
2025-05-15
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on Journey Medical to $10 from $10.50 and keeps a Buy rating on the shares following the Q1 report. The firm adjusted its model lower due to Journey's legacy business trends.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Journey Medical Corp (DERM.O) is 62.48, compared to its 5-year average forward P/E of 15.27. For a more detailed relative valuation and DCF analysis to assess Journey Medical Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
15.27
Current PE
62.48
Overvalued PE
98.81
Undervalued PE
-68.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
40.30
Undervalued EV/EBITDA
-14.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.24
Current PS
0.00
Overvalued PS
1.85
Undervalued PS
0.64
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DERM News & Events

Events Timeline

(ET)
2025-11-12
16:06:30
Journey Medical announces Q3 earnings per share of 9 cents, surpassing consensus estimate of 4 cents.
select
2025-10-24 (ET)
2025-10-24
08:31:57
Journey Medical Unveils Efficacy Results from Two Studies on Emrosi
select
2025-08-12 (ET)
2025-08-12
16:16:57
Journey Medical reports Q2 EPS (16c) vs. (17c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13NASDAQ.COM
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates

  • Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.

  • Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.

  • Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.

  • Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."

[object Object]
Preview
9.0
10-24Newsfilter
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference

  • FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.

  • Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.

  • Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.

  • Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.

[object Object]
Preview
9.0
10-24NASDAQ.COM
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea

  • Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.

  • Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Journey Medical Corp (DERM) stock price today?

The current price of DERM is 7.81 USD — it has increased 1.56 % in the last trading day.

arrow icon

What is Journey Medical Corp (DERM)'s business?

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

arrow icon

What is the price predicton of DERM Stock?

Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Journey Medical Corp (DERM)'s revenue for the last quarter?

Journey Medical Corp revenue for the last quarter amounts to 17.63M USD, increased 20.52 % YoY.

arrow icon

What is Journey Medical Corp (DERM)'s earnings per share (EPS) for the last quarter?

Journey Medical Corp. EPS for the last quarter amounts to -0.09 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Journey Medical Corp (DERM)'s fundamentals?

The market is revising Downward the revenue expectations for Journey Medical Corporation (DERM) for FY2025, with the revenue forecasts being adjusted by -6.26% over the past three months. During the same period, the stock price has changed by 11.41%.
arrow icon

How many employees does Journey Medical Corp (DERM). have?

Journey Medical Corp (DERM) has 41 emplpoyees as of December 05 2025.

arrow icon

What is Journey Medical Corp (DERM) market cap?

Today DERM has the market capitalization of 211.93M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free